Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 77
Filtrer
1.
Arch Pediatr ; 29(7): 516-525, 2022 Oct.
Article de Anglais | MEDLINE | ID: mdl-36109286

RÉSUMÉ

Baby-led weaning (BLW), proposed as a new form of complementary feeding, has emerged as a real trend phenomenon in the media. Infants are seated at the family table from the age of 6 months, facing the foods they grab and bring to their mouth: they decide which foods they want to eat and what amount. The consumption of mashed foods and the use of a spoon are totally discouraged. BLW is increasingly used in nurseries and centers of young children. A bibliographic search carried out between 2000 and 2021 found 423 articles, of which 38 were selected. The clinical studies selected are 11 cross-sectional observational studies and two randomized controlled studies. BLW promotes breastfeeding, the early introduction of morsels, the respect of the child's appetite, the use of unprocessed foods, and the choice of "homemade" and friendliness. These benefits can nonetheless be reached with usual complementary feeding (SCF), according to current recommendations. Other benefits are claimed without scientific evidence such as easier achievement of dietary complementary feeding and an optimal growth with prevention of excess weight gain. BLW has some obvious downsides. The infant may not get enough energy, iron, zinc, vitamins, and other nutrients, or too much protein, saturated fat, salt, or sugar. The risk of choking, which must be distinguished from the physiological gagging reflex, has not been ruled out by scientific studies. Currently, the Nutrition Committee of the French Pediatric Society considers that the data published to date in terms of benefits and risks of BLW do not lend themselves to advice for this practice in preference over SCF carried out according to current recommendations.


Sujet(s)
Comportement alimentaire , Phénomènes physiologiques nutritionnels chez le nourrisson , Allaitement naturel , Enfant , Enfant d'âge préscolaire , Études transversales , Comportement alimentaire/physiologie , Femelle , Humains , Nourrisson , Comportement du nouveau-né et du nourrisson , Aliment du nourrisson au cours de la première année , Phénomènes physiologiques nutritionnels chez le nourrisson/physiologie , Fer , Sucres , Vitamines , Sevrage , Zinc
2.
Arch Pediatr ; 29(1): 1-11, 2022 Jan.
Article de Anglais | MEDLINE | ID: mdl-34758930

RÉSUMÉ

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that occurs mostly in the context of insulin resistance and obesity. It has rapidly evolved into the most common cause of liver disease among children. The incidence is high in obese children and a greater risk of disease progression is associated with severe obesity, highlighting the role of nutrition. To date, there is no consensus on NAFLD management. This is a narrative review of clinical studies on the potential benefit of nutritional interventions, including lifestyle modifications, vitamins, docosahexaenoic acid, and probiotics in children with NAFLD. The Comité de nutrition de la Société Française de Pédiatrie (CN-SFP) emphasizes the effect of limiting added sugar intake, i.e., fructose or sucrose-containing beverages, and promoting physical activity in the care of NAFLD.


Sujet(s)
Mode de vie , Stéatose hépatique non alcoolique/thérapie , État nutritionnel , Obésité pédiatrique/complications , Enfant , Régime alimentaire , Hydrates de carbone alimentaires , Matières grasses alimentaires , Acides gras omega-3 , Fructose/effets indésirables , Humains , Foie , Obésité pédiatrique/thérapie , Probiotiques
4.
Mol Genet Metab ; 132(4): 215-219, 2021 04.
Article de Anglais | MEDLINE | ID: mdl-33610470

RÉSUMÉ

BACKGROUND: A subset of patients with phenylketonuria benefit from treatment with tetrahydrobiopterin (BH4), although there is no consensus on the definition of BH4 responsiveness. The aim of this study therefore was to gain insight into the definitions of long-term BH4 responsiveness being used around the world. METHODS: We performed a web-based survey targeting healthcare professionals involved in the treatment of PKU patients. Data were analysed according to geographical region (Europe, USA/Canada, other). RESULTS: We analysed 166 responses. Long-term BH4 responsiveness was commonly defined using natural protein tolerance (95.6%), improvement of metabolic control (73.5%) and increase in quality of life (48.2%). When a specific value for a reduction in phenylalanine concentrations was reported (n = 89), 30% and 20% were most frequently used as cut-off values (76% and 19% of respondents, respectively). When a specific relative increase in natural protein tolerance was used to define long-term BH4 responsiveness (n = 71), respondents most commonly reported cut-off values of 30% and 100% (28% of respondents in both cases). Respondents from USA/Canada (n = 50) generally used less strict cut-off values compared to Europe (n = 96). Furthermore, respondents working within the same center answered differently. CONCLUSION: The results of this study suggest a very heterogeneous situation on the topic of defining long-term BH4 responsiveness, not only at a worldwide level but also within centers. Developing a strong evidence- and consensus-based definition would improve the quality of BH4 treatment.


Sujet(s)
Bioptérines/analogues et dérivés , Phénylalanine/génétique , Phénylcétonuries/traitement médicamenteux , Bioptérines/effets indésirables , Bioptérines/usage thérapeutique , Canada/épidémiologie , Europe/épidémiologie , Humains , Phénylalanine/sang , Phenylalanine 4-monooxygenase/génétique , Phénylcétonuries/sang , Phénylcétonuries/épidémiologie , Phénylcétonuries/anatomopathologie , États-Unis/épidémiologie
6.
Orphanet J Rare Dis ; 15(1): 230, 2020 09 01.
Article de Anglais | MEDLINE | ID: mdl-32873338

RÉSUMÉ

An amendment to this paper has been published and can be accessed via the original article.

7.
Orphanet J Rare Dis ; 15(1): 171, 2020 06 30.
Article de Anglais | MEDLINE | ID: mdl-32605583

RÉSUMÉ

BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine. MAIN BODY: In 2017 the first European PKU Guidelines were published. These guidelines contained evidence based and/or expert opinion recommendations regarding diagnosis, treatment and care for patients with PKU of all ages. This manuscript is a supplement containing the practical application of the dietary treatment. CONCLUSION: This handbook can support dietitians, nutritionists and physicians in starting, adjusting and maintaining dietary treatment.


Sujet(s)
Phenylalanine 4-monooxygenase , Phénylcétonuries , Régime alimentaire , Humains , Phénylalanine , Tyrosine
9.
Arch Pediatr ; 26(7): 437-441, 2019 Oct.
Article de Anglais | MEDLINE | ID: mdl-31500920

RÉSUMÉ

Avoidant/restrictive food intake disorder (ARFID) has recently been added to the DSM V (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) as a new class of eating disorders (EDs). ARFID is characterized by a lack of interest in eating or avoiding specific types of foods because of their sensory characteristics. This avoidance results in decreased nutritional intake, eventually causing nutritional deficiencies. In severe cases, ARFID can lead to dependence on oral nutritional supplements, which interferes with psychosocial functioning. The prevalence of ARFID can be as high as 3% in the general population, and it is often associated with gastrointestinal symptoms and mainly appears in children with anxiety disorders. Given the high prevalence of ARFID, a rapid and systematic nutrition survey should be conducted during every pediatric consultation. Its treatment should also be adapted depending on the severity of the nutritional problem and may involve hospitalization with multidisciplinary care (pediatrician, nutritional therapist, dietitian, psychologists, and speech therapists).


Sujet(s)
Trouble de l'alimentation sélective et évitante , Malnutrition/étiologie , Anxiété/complications , Anxiété/physiopathologie , Anxiété/psychologie , Anxiété/thérapie , Enfant , Humains , Malnutrition/diagnostic , Malnutrition/psychologie , Malnutrition/thérapie , Pédiatrie , Facteurs de risque
10.
Arch Pediatr ; 26(4): 238-246, 2019 May.
Article de Anglais | MEDLINE | ID: mdl-30979632

RÉSUMÉ

Foods for special medical purposes (FSMPs) with a protein fraction made of hydrolyzed rice protein (HRPs) have been on the market in Europe since the 2000s for the treatment of cow's milk protein allergy (CMPA). HRP formulas (HRPFs) are proposed as a plant-based alternative to cow's milk protein-based extensively hydrolyzed formulas (CMP-eHF) beside the soy protein formulas whose use in CMPA is controversial. HRPFs do not contain phytoestrogens and are derived from non-genetically modified rice. HRPFs are strictly plant-based apart from the addition of vitamin D3 (cholecalciferol). As the amino acid content of rice proteins differs from that of human milk proteins, the protein quality of these formulas is improved by supplementation with free lysine, threonine, and tryptophan. The consumption of HRPFs has risen: for example, in France HRPFs account for 4.9% in volume of all formulas for children aged 0-3 years. Several studies have shown the adequacy of HRPFs in treating CMPA. They ensure satisfactory growth from the 1st weeks of life for infants and toddlers, both in healthy children and in those with CMPA. HRPFs can be used to treat children with CMPA either straightaway or in second intention in cases of poor tolerance to CMP-eHF for organoleptic reasons or for lack of efficacy. In France, the cost of HRPFs is close to that of regular infant or follow-on formulas.


Sujet(s)
Préparation pour nourrissons , Hypersensibilité au lait/diétothérapie , Oryza , Protéines de légume/administration et posologie , Hydrolysats de protéines/administration et posologie , Hydrates de carbone alimentaires/administration et posologie , Hydrates de carbone alimentaires/analyse , Humains , Nourrisson , Préparation pour nourrissons/composition chimique , Lipides/administration et posologie , Lipides/analyse , Protéines de lait/effets indésirables , Protéines de légume/analyse , Hydrolysats de protéines/analyse
11.
Arch Pediatr ; 2018 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-29914755

RÉSUMÉ

Inherited metabolic diseases (IMD) form a heterogeneous group of genetic disorders that surface primarily during childhood and result in significant morbidity and mortality. A prevalence of 1 in 2500-5000 live births is often reported. The transfer of adolescents from pediatric care to adult health facilities is often difficult for patients and their families and can lead to a breakdown in medical follow-up and therefore serious complications. Existing recommendations for the successful transition of patients with chronic disorders do not specifically address patients with IMDs associated with dietary treatment. Here, the French network for rare inherited metabolic diseases (G2M) presents its reflections and recommendations for a successful transition. Preparations for the transfer must be made well in advance. The transfer must aim for adolescents gaining autonomy by making them responsible and providing them with the knowledge that will enable them to manage their care themselves, know how to react appropriately if there is any change in their condition, and move comfortably within the adult healthcare system. This requires the active participation of the patient, his or her family, and pediatric and adult care teams. It involves multidisciplinary management plus the production and maintenance of an educational therapy program. Finally, the identification of physicians and dietitians trained in IMDs, relevant subspecialists, and even expert patients could improve the continuum of complete and appropriate care for these patients within adult medicine.

12.
Acta Neurol Scand ; 137(5): 452-461, 2018 May.
Article de Anglais | MEDLINE | ID: mdl-29635721

RÉSUMÉ

OBJECTIVES: Rhabdomyolysis and myalgia are common conditions, and mutation in the ryanodine receptor 1 gene (RYR1) is suggested to be a common cause. Due to the large size of RYR1, however, sequencing has not been widely accessible before the recent advent of next-generation sequencing technology and limited phenotypic descriptions are therefore available. MATERIAL & METHODS: We present the medical history, clinical and ancillary findings of patients with RYR1 mutations and rhabdomyolysis and myalgia identified in Denmark, France and The Netherlands. RESULTS: Twenty-two patients with recurrent rhabdomyolysis (CK > 10 000) or myalgia with hyperCKemia (>1.5 × ULN) and a RYR1 mutation were identified. One had mild wasting of the quadriceps muscle, but none had fixed weakness. Symptoms varied from being restricted to intense exercise to limiting ADL function. One patient developed transient kidney failure during rhabdomyolysis. Two received immunosuppressants on suspicion of myositis. None had episodes of malignant hyperthermia. Muscle biopsies were normal, but CT/MRI showed muscle hypertrophy in most. Delay from first symptom to diagnosis was 12 years on average. Fifteen different dominantly inherited mutations were identified. Ten were previously described as pathogenic and 5 were novel, but rare/absent from the background population, and predicted to be pathogenic by in silico analyses. Ten of the mutations were reported to give malignant hyperthermia susceptibility. CONCLUSION: Mutations in RYR1 should be considered as a significant cause of rhabdomyolysis and myalgia syndrome in patients with the characteristic combination of rhabdomyolysis, myalgia and cramps, creatine kinase elevation, no weakness and often muscle hypertrophy.


Sujet(s)
Myalgie/génétique , Rhabdomyolyse/génétique , Canal de libération du calcium du récepteur à la ryanodine/génétique , Adolescent , Adulte , Enfant , Danemark , Femelle , France , Génotype , Humains , Mâle , Adulte d'âge moyen , Mutation , Myalgie/physiopathologie , Pays-Bas , Phénotype , Rhabdomyolyse/physiopathologie , Syndrome , Jeune adulte
13.
Arch Pediatr ; 25(4): 286-294, 2018 May.
Article de Anglais | MEDLINE | ID: mdl-29656825

RÉSUMÉ

Due to transient gut immaturity, most very preterm infants receive parenteral nutrition (PN) in the first few weeks of life. Yet providing enough protein and energy to sustain optimal growth in such infants remains a challenge. Extrauterine growth restriction is frequently observed in very preterm infants at the time of discharge from hospital, and has been found to be associated with later impaired neurodevelopment. A few recent randomized trials suggest that intensified PN can improve early growth; whether or not such early PN improves long-term neurological outcome is still unclear. Several other questions regarding what is optimal PN for very preterm infants remain unanswered. Amino acid mixtures designed for infants contain large amounts of branched-chain amino acids and taurine, but there is no consensus on the need for some nonessential amino acids such as glutamine, arginine, and cysteine. Whether excess growth in the first few weeks of life, at a time when very preterm infants receive PN, has an imprinting effect, increasing the risk of metabolic or vascular disease at adulthood continues to be debated. Even though uncertainty remains regarding the long-term effect of early PN, it appears reasonable to propose intensified initial PN. The aim of the current position paper is to review the evidence supporting such a strategy with regards to the early phase of nutrition, which is mainly covered by parenteral nutrition. More randomized trials are, however, needed to further support this type of approach and to demonstrate that this strategy improves short- and long-term outcome.


Sujet(s)
Prématuré , Nutrition parentérale/méthodes , Acides aminés/administration et posologie , Composition corporelle , Développement de l'enfant , Électrolytes/administration et posologie , Glucose/administration et posologie , Troubles de la croissance/prévention et contrôle , Humains , Nouveau-né , Lipides/administration et posologie , État nutritionnel , Eau/administration et posologie
15.
Arch Pediatr ; 25(3): 236-243, 2018 Apr.
Article de Anglais | MEDLINE | ID: mdl-29576253

RÉSUMÉ

Cow's milk is one of the most common foods responsible for allergic reactions in children. Cow's milk allergy (CMA) involves immunoglobulin E (IgE)- and non-IgE-mediated reactions, the latter being both variable and nonspecific. Guidelines thus emphasize the need for physicians to recognize the specific syndromes of CMA and to respect strict diagnostic modalities. Whatever the clinical pattern of CMA, the mainstay of treatment is the elimination from the diet of cow's milk proteins. The challenge is that both the disease and the elimination diet may result in insufficient height and weight gain and bone mineralization. If, during CMA, the mother is not able or willing to breastfeed, the child must be fed a formula adapted to CMA dietary management, during infancy and later, if the disease persists. This type of formula must be adequate in terms of allergic efficacy and nutritional safety. In older children, when CMA persists, the use of cow's milk baked or heated at a sufficient temperature, frequently tolerated by children with CMA, may help alleviate the stringency of the elimination diet. Guidance on the implementation of the elimination diet by qualified healthcare professionals is always necessary. This guidance should also include advice to ensure adequate bone growth, especially relating to calcium intake. Specific attention should be given to children presenting with several risk factors for weak bone mineral density, i.e., multiple food allergies, vitamin D deficiency, poor sun exposure, steroid use, or severe eczema. When CMA is outgrown, a prolonged elimination diet may negatively impact the quality of the diet over the long term.


Sujet(s)
Hypersensibilité au lait/thérapie , Animaux , Maladies osseuses métaboliques/prévention et contrôle , Allaitement naturel , Cuisine (activité) , Services de diététique et de nutrition , Troubles de la croissance/étiologie , Troubles de la croissance/prévention et contrôle , Humains , Nourrisson , Préparation pour nourrissons , Hypersensibilité au lait/immunologie , Guides de bonnes pratiques cliniques comme sujet , Facteurs de risque
17.
Clin Genet ; 93(1): 191-193, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-28742214

RÉSUMÉ

Folate and vitamin B12 are needed for the proper embryo-fetal development possibly through their interacting role in the 1-carbon metabolism. Folate fortification reduces the prevalence of complex birth defects, and more specifically neural tube defects (NTDs). GIF and FUT2 are 2 genes associated with the uptake and blood level of vitamin B12. We evaluated GIF and FUT2 as predictors of severe birth defects, in 183 aborted fetuses compared with 375 healthy newborns. The GIF290C allele frequency was estimated to 0.4% in healthy newborns and to 8.1% in NTD fetuses (odds ratio 17.8 [95% confidence interval CI: 4.0-77.6]). The frequency of FUT2 rs601338 secretor variant was not different among groups. The GIF 290C heterozygous/FUT2 rs601338 secretor variant combined genotype was reported in 6 of the 37 NTD fetuses, but not in other fetuses and healthy newborns (P < .0001). This GIF/FUT2 combined genotype has been previously reported in children with congenital gastric intrinsic factor (GIF) deficiency, with respective consequences on B12 binding activity and GIF secretion. In conclusion, a genotype reported in congenital GIF deficiency produces also severe forms of NTD. This suggests that vitamin B12 delivery to neural tissue by the CUBN/GIF pathway could play a role in the neural tube closure mechanisms.


Sujet(s)
Fucosyltransferases/génétique , Prédisposition génétique à une maladie/génétique , Facteur intrinsèque/génétique , Mutation , Anomalies du tube neural/génétique , Polymorphisme de nucléotide simple , Études de cohortes , Foetus/métabolisme , Fréquence d'allèle , Génotype , Hétérozygote , Humains , Nouveau-né , Analyse de séquence d'ADN/méthodes ,
18.
Mol Genet Metab Rep ; 13: 83-89, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-29021961

RÉSUMÉ

BACKGROUND: The definitive dietary management of propionic acidaemia (PA) is unknown although natural protein restriction with adequate energy provision is of key importance. AIM: To describe European dietary practices in the management of patients with PA prior to the publication of the European PA guidelines. METHODS: This was a cross-sectional survey consisting of 27 questions about the dietary practices in PA patients circulated to European IMD dietitians and health professionals in 2014. RESULTS: Information on protein restricted diets of 186 PA patients from 47 centres, representing 14 European countries was collected. Total protein intake [PA precursor-free L-amino acid supplements (PFAA) and natural protein] met WHO/FAO/UNU (2007) safe protein requirements for age in 36 centres (77%). PFAA were used to supplement natural protein intake in 81% (n = 38) of centres, providing a median of 44% (14-83%) of total protein requirement. Seventy-four per cent of patients were prescribed natural protein intakes below WHO/FAO/UNU (2007) safe levels in one or more of the following age groups: 0-6 m, 7-12 m, 1-10 y, 11-16 y and > 16 y. Sixty-three per cent (n = 117) of patients were tube fed (74% gastrostomy), but only 22% received nocturnal feeds. CONCLUSIONS: There was high use of PFAA with intakes of natural protein commonly below WHO/FAO/UNU (2007) safe levels. Optimal dietary management can only be determined by longitudinal, multi-centre, prospective case controlled studies. The metabolic instability of PA and small patient cohorts in each centre ensure that this is a challenging undertaking.

19.
Orphanet J Rare Dis ; 12(1): 162, 2017 10 12.
Article de Anglais | MEDLINE | ID: mdl-29025426

RÉSUMÉ

Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine. If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems. PKU management differs widely across Europe and therefore these guidelines have been developed aiming to optimize and standardize PKU care. Professionals from 10 different European countries developed the guidelines according to the AGREE (Appraisal of Guidelines for Research and Evaluation) method. Literature search, critical appraisal and evidence grading were conducted according to the SIGN (Scottish Intercollegiate Guidelines Network) method. The Delphi-method was used when there was no or little evidence available. External consultants reviewed the guidelines. Using these methods 70 statements were formulated based on the highest quality evidence available. The level of evidence of most recommendations is C or D. Although study designs and patient numbers are sub-optimal, many statements are convincing, important and relevant. In addition, knowledge gaps are identified which require further research in order to direct better care for the future.


Sujet(s)
Phénylcétonuries/diagnostic , Phénylcétonuries/thérapie , Guides de bonnes pratiques cliniques comme sujet , Europe , Humains
20.
Arch Pediatr ; 24(11): 1129-1136, 2017 Nov.
Article de Français | MEDLINE | ID: mdl-28947248

RÉSUMÉ

Cyclic vomiting syndrome (CVS) is a misrecognized and probably underdiagnosed disease that can affect up to 1.9% of the pediatric population and can occupy 15% of these children's time. It is characterized by acute attacks of vomiting, occurring with such a strict frequency that some parents can predict the date of their child's next attack. The pathophysiology of CVS is unclear, although the literature recognizes a common origin with migraine headaches, which has the same acute and prophylactic treatment. CVS is now included in the larger group of diseases called "episodic symptoms related to migraine" previously known as "childhood periodic syndromes." To distinguish between real CVS and other differential diagnoses can challenge the clinician. Additional investigations must be considered in accordance with the clinical presentation. Appropriate management of CVS should lead to an improvement in quality of life and school attendance.


Sujet(s)
Vomissement , Enfant , Arbres de décision , Humains , Vomissement/diagnostic , Vomissement/physiopathologie , Vomissement/thérapie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...